Hemab Therapeutics Holdings, Inc. Common Stock (COAG) vs Kardigan, Inc. (KARD)
A side-by-side comparison of Hemab Therapeutics Holdings, Inc. Common Stock and Kardigan, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$28.69HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
KARD
Kardigan, Inc.
$13.69HealthcareDelayed quote: Oct 6, 2026, 10:09 AM EDT
Total return — COAG vs KARD
growth of $100 · dividends reinvested · last 1yCOAG +4.6% (+4.6%/yr)KARD -30.7% (-30.7%/yr)COAG compounded faster over this window
COAG KARD
COAG vs KARD: by the numbers
- •COAG is the larger company ($1.34B vs $1.22B market cap).
Metrics side by side
Valuation
| Metric | COAG | KARD |
|---|---|---|
| P/B ratio | 2.95 | 1.99 |
Profitability
| Metric | COAG | KARD |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROIC | -38.09% | -57.11% |
Go deeper
Dig into the metrics
Hemab Therapeutics Holdings, Inc. Common Stock ROEKardigan ROEHemab Therapeutics Holdings, Inc. Common Stock operating marginKardigan operating marginHemab Therapeutics Holdings, Inc. Common Stock revenue growthKardigan revenue growthHemab Therapeutics Holdings, Inc. Common Stock free cash flowKardigan free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.